Drugs / Prime-2-CoV_Beta
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05389319 | Jun 2022 → Dec 2026 expected | COVID-19 | University Hospital Tuebingen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05367843 | Jun 2022 → Jul 2023 | COVID-19 | Speransa Therapeutics | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prime-2-CoV_Beta | “Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine that co-expresses Spike (S) and Nucleocapsid (N) antigens.” PMID 39397784 ↗ Oct 2024 |
| Modality | Vaccine | “Prime-2-CoV_Beta is an orf virus (ORFV) based multi-antigen COVID-19 vaccine” PMID 39397784 ↗ Oct 2024 |
| Route | Intramuscular | “1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1” NCT05389319 ↗ |